Last reviewed · How we verify
NCT04655937: WAterS
Wellbeing After Stroke (WAterS): Supporting Adjustment and Wellbeing After Stroke
Phase 1 trial testing Acceptance and Commitment Therapy in Stroke in 20 participants. Completed in 1 May 2023.
15 March 2021
Quick facts
| Lead sponsor | University of Manchester |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 5 January 2021 |
| Primary completion | 15 March 2021 |
| Estimated completion | 1 May 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Acceptance and Commitment Therapy
Conditions studied
- Stroke — all drugs for Stroke →
- Psychological Distress — all drugs for Psychological Distress →
- Cognitive Dysfunction — all drugs for Cognitive Dysfunction →
- Communication Disorders — all drugs for Communication Disorders →
Sponsor
University of Manchester
Who can join
18 and older, any sex, with Stroke or Psychological Distress. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stroke survivors face a range of mental health challenges adjusting post-stroke. There is a lack of treatment options and clinical psychologist workforce to deliver support. Acceptance and Commitment Therapy (ACT) has been used successfully in clinical services to improve wellbeing. The investigators worked with stroke survivors, health care professionals and researchers to co-develop group ACT therapy, specifically for stroke survivors, to be delivered using video calling (Zoom). Staff training and supervision programmes were also developed to equip Stroke Association workforce (paraprofessionals) to deliver ACT. The current study will recruit and train up to 10 professionals with some experience of supporting stroke survivors but no experience of ACT. We then aim to recruit up to 30 stroke survivors in the community who are at least 4 months post-stroke and experiencing distress adjusting to their stroke. The investigators aimed to make everything accessible for people with mild/moderate difficulties with thinking and communicating. Recruitment took place across England, over a 6 month period. The study will test how feasible and acceptable it is to deliver the co-developed, remote ACT intervention to stroke survivors, as well as the feasibility of collecting outcomes data: 1. Participants will be invited to consent to complete online measures of well-being every 3 months for up to 12 months (taking around 20 minutes), with the option to participate in group intervention. Those who don't opt for groups will not be treated but will be followed up about their wellbeing, if they agree. 2. Those who opt to attend groups will be randomly assigned into intervention groups A, B, or C and receive the ACT intervention, involving 9 weekly sessions and homework. Data will be collected on how successfully the groups are delivered and how acceptable they are / how to improve them, through online surveys, feedback questionnaires and interviews. UPDATE May 2023: The investigators had initially intended to run an active comparator arm of social support and randomly allocated people to arms \*and\* groups. However, the design changed after the COVID-19 pandemic, meaning that the planning phases took longer than expected in order to pivot all study components to be deliverable online. \*Please see references section for our findings and publications
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pharmacological, non-invasive brain stimulation and psychological interventions, and their combination, for treating depression after stroke.
Allida SM, Hsieh CF, Cox KL, Patel K, et al · · 2023 · cited 11× · PMID 37417452 · DOI 10.1002/14651858.cd003437.pub5 -
Wellbeing After Stroke (WAterS): Feasibility Testing of a Co-developed Acceptance and Commitment Therapy Intervention to Support Psychological Adjustment After Stroke.
Patchwood E, Foote H, Vail A, Cotterill S, et al · · 2024 · cited 10× · PMID 38505946 · DOI 10.1177/02692155241239879
Verify or expand the search:
- PubMed search for NCT04655937
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Acceptance and Commitment Therapy
Trials testing the same drug.
- NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges · NA · not yet recruiting
- NCT07345806 — A Pilot Study on an ACT-Based Program for Individuals With Special Needs and Their Caregivers · NA · recruiting
- NCT07512388 — Acceptance and Commitment Therapy for Post-Stroke Adjustment Via Telerehabilitation · NA · active not recruiting
- NCT06647589 — Acceptance and Commitment Therapy for Religious OCD · NA · recruiting
- NCT06971861 — Just ACT for Student Well-being · NA · recruiting
Other recruiting trials for Stroke
Currently open trials in the same condition.
- NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
- NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
- NCT07356011 — Exoskeleton for Balance · NA · recruiting
- NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
- NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
Other University of Manchester trials
Trials by the same sponsor.
- NCT07506096 — Using IF-THEN Plans to Support Healthcare Professionals in Raising Patient Safety Concerns · NA · not yet recruiting
- NCT07084090 — Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care · NA · not yet recruiting
- NCT07494760 — A Feasibility Randomised Control Trial to Evaluate Early Perinatal Bereavement Counselling for Parents Who Have Experien · NA · not yet recruiting
- NCT07372885 — GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia · Phase 1, PHASE2 · not yet recruiting
- NCT07381894 — Multicentre Hypertrophic Cardiomyopathy Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04655937 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Manchester
- Last refreshed: 10 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04655937.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing